Antisense Oligonucleotide Therapeutics Pipeline Insight Summary
DelveInsight’s “Antisense Oligonucleotide Therapeutics Pipeline Insight 2026” report provides comprehensive insights about 150+ companies and 200+ pipeline drugs in the Antisense Oligonucleotide Therapeutics pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. This intelligence resource equips stakeholders – from pharmaceutical researchers to investors – with the actionable data needed to navigate the evolving Antisense Oligonucleotide Therapeutics landscape confidently.
Discover Leading Antisense Oligonucleotide Therapeutics Companies and Their Clinical Stage Candidates Now
Antisense Oligonucleotide Disease Understanding
Antisense Oligonucleotide Overview
Aberrant protein expression or metabolism underlies a wide range of severe diseases, and since proteins are ultimately translated from messenger RNA (mRNA), targeting RNA provides a direct strategy to modulate disease-causing proteins. Advances in RNA biology have further expanded this approach by revealing the regulatory roles of non-coding RNAs, including microRNAs, transfer RNA-derived small RNAs, pseudogenes, PIWI-interacting RNAs, long non-coding RNAs, and circular RNAs, all of which contribute to gene expression control. This has established antisense oligonucleotides (ASOs) as a therapeutic platform capable of targeting pre-mRNA, mRNA, or non-coding RNAs through sequence-specific Watson-Crick base pairing, enabling precise modulation of pathogenic gene expression.
Unlike conventional small-molecule drugs, ASOs offer flexible and highly specific RNA targeting, making them particularly valuable for rare and genetic disorders. Continued advances in chemical modifications and delivery technologies have significantly enhanced their stability, efficacy, and clinical applicability. The growing success of nucleic acid-based therapeutics, including recent regulatory approvals, has further accelerated interest in the field, with multiple ASO candidates now in clinical development across diverse disease areas such as neurological, metabolic, cardiovascular, inflammatory, and infectious disorders.
Antisense oligonucleotides (ASOs) were first shown to inhibit gene expression by binding complementary mRNA through Watson-Crick base pairing, enabling sequence-specific regulation. Their mechanisms of action are broadly divided into RNA degradation and RNA modulation. In RNase H1-mediated degradation, ASOs form DNA-RNA hybrids that trigger enzymatic cleavage of the target RNA, a mechanism commonly used by approved therapies, with gapmer designs enhancing stability and activity. RNA interference similarly silences genes through Argonaute 2 within the RNA-induced silencing complex, which cleaves target mRNA guided by small interfering RNA.
In contrast, steric-blocking ASOs inhibit gene expression without RNA degradation by physically preventing ribosome assembly or RNA-protein interactions and can also disrupt microRNA function. ASOs may additionally modulate pre-mRNA splicing by promoting exon skipping or inclusion to restore or alter protein production.
The clinical application of antisense oligonucleotides (ASOs) has long been limited by challenges in efficient and targeted delivery, prompting the development of multiple delivery strategies. Enhanced stabilization chemistry has been widely used for small interfering RNA delivery, particularly through conjugation with N-acetylgalactosamine, which enables selective uptake by hepatocytes via the asialoglycoprotein receptor while also improving stability in biological fluids and reducing immune activation.
Nanoparticle-based systems, including polymeric carriers such as PLGA, PBAE, and PEI, have also been explored. While cationic polymers like PBAE and PEI enhance cellular uptake through endosomal escape mechanisms, their clinical translation has been constrained by toxicity and non-specific interactions. PLGA offers improved biocompatibility and regulatory acceptance.
Lipid-based platforms, including liposomes, lipoplexes, and lipid nanoparticles, provide another widely used approach. Polyethylene glycol modification extends circulation time and facilitates tumor accumulation via the enhanced permeability and retention effect, as exemplified by approved lipid nanoparticle-based siRNA therapeutics.
MicroRNAs (miRNAs) are short non-coding RNAs that regulate key processes involved in cell identity, development, and gene expression, and their dysregulation is linked to a wide range of malignant and non-malignant diseases. Antisense oligonucleotides have been developed to selectively inhibit disease-associated miRNAs by binding to complementary sequences and preventing their functional activity.
A notable example is miravirsen, an LNA- and phosphorothioate-modified oligonucleotide targeting miR-122 for hepatitis C virus infection, although its clinical development was limited by safety concerns. Another approach includes antimiR-21 (RG-012), developed for Alport syndrome to slow renal fibrosis progression and granted orphan drug designation in the United States and Europe.
Oncogenic miRNAs have also been therapeutically targeted, such as miR-155, which is frequently upregulated in lymphomas. Cobomarsen (MRG-106), an LNA-based inhibitor of miR-155, is currently under clinical evaluation for T-cell lymphomas. These strategies exploit the miRNA biogenesis pathway, in which primary miRNAs are processed into precursor and mature forms that are incorporated into the RNA-induced silencing complex with Argonaute proteins, enabling sequence-specific regulation of target mRNAs through translational repression or degradation, thereby providing a mechanistic basis for antisense-mediated miRNA inhibition.
“Antisense Oligonucleotide Therapeutics Pipeline Insight 2026” report by DelveInsight outlays comprehensive insights into the present scenario and growth prospects across the indication. A detailed picture of the Antisense Oligonucleotide Therapeutics pipeline landscape is provided, which includes the disease overview and treatment guidelines. The assessment section of the report includes an in-depth commercial and clinical assessment of pipeline products under development.
The Antisense Oligonucleotide Therapeutics Pipeline report provides detailed drug descriptions, including mechanism of action, clinical studies, NDA approvals (if any), and product development activities comprising technology, collaborations, licensing, mergers and acquisitions, funding, designations, and other product-related details.
Discover How These Emerging Antisense Oligonucleotide Therapies Could Shape the Future of RNA-Targeted Treatment
Antisense Oligonucleotide Pipeline Report Highlights
Companies and academic institutions are actively working to assess challenges and identify opportunities that could influence Antisense Oligonucleotide Therapeutics R&D. Therapies under development are focused on novel approaches to treat or improve Antisense Oligonucleotide Therapeutics.
Antisense Oligonucleotide Emerging Drugs Analysis
This segment of the report provides detailed analysis of various drugs in different stages of clinical development, including Phase III, Phase II, Phase I, Preclinical, and Discovery stages. It also provides insights into clinical trial details, pharmacological action, agreements and collaborations, as well as the latest news and press releases.
Antisense Oligonucleotide Emerging Drugs
- DYNE-101: Dyne Therapeutics
DYNE-101 is Dyne’s therapeutic candidate being developed for people living with myotonic dystrophy type 1 (DM1). DYNE-101 consists of an antigen-binding fragment antibody (Fab) conjugated to an antisense oligonucleotide (ASO) to enable targeted muscle tissue delivery with the goal of reducing toxic DMPK RNA in the nucleus, releasing splicing proteins, allowing normal mRNA processing and translation of normal proteins, and potentially stopping or reversing the disease. Currently, the drug is in Phase III clinical development for myotonic dystrophy.
- Pelacarsen: Novartis
Pelacarsen (TQJ230), also known as IONIS-APO(a)-LRx and AKCEA-APO(a)-LRx, is an investigational antisense medicine designed to reduce apolipoprotein(a) in the liver to lower lipoprotein(a) levels. Elevated Lp(a) is recognized as an independent genetic cause of coronary artery disease, stroke, heart attack, and peripheral arterial disease. The drug is currently in Phase III development for Hyperlipoproteinaemia and Atherosclerosis.
- AHB-137: Ausper Bio
AHB-137 is a novel unconjugated antisense oligonucleotide developed through AusperBio’s proprietary Med-Oligo™ ASO platform for chronic hepatitis B treatment. The dual-mechanism ASO is currently undergoing Phase Ib and Phase II clinical trials and is advancing toward functional cure strategies for HBV infection. The drug is presently in Phase III stage development for Chronic Hepatitis B.
Major Antisense Oligonucleotide Players in Antisense Oligonucleotide
Approximately 150+ key companies are developing therapies for Antisense Oligonucleotide Therapeutics.
Dyne Therapeutics has one of the most advanced pipeline candidates currently in Phase III development, alongside Novartis and Ausper Bio, whose candidates Pelacarsen and AHB-137 have also progressed into Phase III stage development. Growing interest in exon-skipping, RNase H1-mediated degradation, and miRNA-targeted platforms is observed among emerging biotech players.
Key companies in the Antisense Oligonucleotide Therapeutics space include:
- Dyne Therapeutics
- Novartis
- Ausper Bio
- Kardigan
- Wave Life Sciences
- Ionis Pharmaceuticals
- Vanda Pharmaceuticals
- QurAlis Corporation
- ProQR
- Secarna Pharmaceuticals
- And others.
Antisense Oligonucleotide Clinical Trial Phases
The report covers around 200+ products under different stages of clinical development, including:
- Late-stage products (Phase III): Advanced candidates with pivotal trial data, targeting regulatory approval
- Mid-stage products (Phase II): Candidates demonstrating early efficacy and safety with expanded cohort trials
- Early-stage products (Phase I): First-in-human studies assessing safety and dosing profiles
- Preclinical and Discovery stage candidates: Exploratory molecules in laboratory and animal model testing
- Discontinued and inactive candidates: Products that have been halted or deprioritized, providing strategic competitive intelligence
Antisense Oligonucleotide Drug Route of Administration
The pipeline report provides therapeutic assessment based on route of administration categories such as:
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
Antisense Oligonucleotide Product Molecule Type
Products have been categorized under different molecule types, including:
Recombinant fusion proteins
- Small molecules
- Monoclonal antibodies
- Peptides
- Polymers
- Gene therapies
Antisense Oligonucleotide Product Type
Drugs have been categorized into:
- Mono therapies
- Combination therapies
- Mono/Combination therapies
Explore the Full Antisense Oligonucleotide Therapeutics Pipeline Report and Unlock Comprehensive Drug Insights Today
Conclusion
The Antisense Oligonucleotide Therapeutics pipeline is rapidly evolving, with a robust set of candidates spanning RNase H1-mediated degradation, exon-skipping splice modulation, and miRNA-targeted platforms across multiple clinical stages. The growing involvement of 150+ Antisense Oligonucleotide Therapeutics companies and the depth of ongoing clinical trials covering 200+ products signal a highly active and competitive landscape. With advanced candidates like DYNE-101, Pelacarsen, and AHB-137 progressing through Phase III development, and next-generation approaches like ION717, VCA-894A, and QRL-201 advancing through early-to-mid stage development, the pipeline holds strong promise for improving patient outcomes globally. Continued investment, cross-sector collaboration, and strategic pipeline monitoring will be critical to address unmet medical needs and expand the reach of RNA-targeted precision medicine across neurological, metabolic, cardiovascular, inflammatory, and infectious disease areas.
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharmaceutical companies by providing comprehensive end-to-end solutions to improve their performance. It also offers healthcare consulting services that leverage market analysis to accelerate business growth and overcome challenges with practical approaches.
Media contact
Name: Abhishek kumar
E-mail: abhishek@delveinsight.com
